Please assess the completion status of the following clinical trial:

Trial Title: IL-11 in Adults With Von Willebrand Disease Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 years of age and older~* Confirmed type 1 VWD, as defined by low VWF:RCoF or low VWF:Ag and qualitatively normal VWF multimers~* A past bleeding history~* Responsive to DDAVP~* Scheduled elective major surgery or major dental surgery at MUH or PUH~* Willingness to have blood drawn~Exclusion Criteria:~* Presence of other bleeding disorders, acquired Von Willebrand disease, primary thrombocytopenia~* Use of immunomodulatory or experimental drugs, or diuretics~* Pregnant or lactating women or those unwilling to use contraception during study~* Previous cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis~* Past allergic reaction to Neumega or DDAVP~* Surgery within the past 8 weeks~* Inability to comply with study protocol requirements~* Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs~* Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study~* Past allergic reaction to Neumega or DDAVP~* Surgery within the past 8 weeks~* Inability to comply with study protocol requirements~* Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs~* Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neumega (Interleukin 11, IL-11) (Type: EXPERIMENTAL): Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).